Invivo Therapeutics confirms huge improvement of Second and Third Patients done with Neuro-Spinal Scaffold Print E-mail
By David Fowler   
Monday, 06 July 2015 16:34

Invivo Therapeutics Holdings Corp. (NASDAQ:NVIV) has confirmed an update for one-month post-implant for third study patient as well as six-month post-implant update for second study patient in present pilot trial of investigational Neuro-Spinal Scaffold in patients having acute spinal cord injury.

The duration between one-month post-injury and implantation of third study patient ensured full AIS A spinal cord injury to unfulfilled AIS B spinal cord injury.

The patient got sacral sensation having an improved bladder function. Earlier less than 4% of patients with high thoracic neurologic level of injury changed from AIS A to AIS B in first month after injury.

The second patient showed improvement in sensory function with little sensation existing in five dermatome levels lesser on right side vis-a-vis three-month assessment.


The Neuro-Spinal Scaffold was done in patients by Dr. Dom Coric of Carolina Neurosurgery as well as Spine Associates, Chief of Neurosurgery at the Carolinas Medical Center (CMC) in Charlotte, NC.

 

The study is driven by Dr. Coric as well as Dr. William Bockenek, Chief Medical Officer of Carolinas Rehabilitation.

 

Coric opined that he is encouraged with third patients neurologic recovery after implantation of investigational Neuro-Spinal Scaffold. 

 

On the other hand, Dr. Bockenek added that it is promising when a patient who is defined in complete spinal cord injury gets categorised as incomplete.

 

Mark Perrin, InVivos CEO, opined that the firm is excited about neurologic progress which each of the three study patients has done till now.

 

It is noteworthy that two patients showed fast improvement within first month post-injury from full to incomplete spinal cord injury.

 

Shares of the company are up 10.22% to $17.26.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter